Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 49.89 CNY 0.26% Market Closed
Market Cap: 37B CNY

Hangzhou Tigermed Consulting Co Ltd
Accrued Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Hangzhou Tigermed Consulting Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Accrued Liabilities
ÂĄ325.8m
CAGR 3-Years
7%
CAGR 5-Years
27%
CAGR 10-Years
35%
WuXi AppTec Co Ltd
SSE:603259
Accrued Liabilities
ÂĄ2.2B
CAGR 3-Years
9%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Accrued Liabilities
ÂĄ845.7m
CAGR 3-Years
14%
CAGR 5-Years
22%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Accrued Liabilities
ÂĄ435.5m
CAGR 3-Years
3%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Genscript Biotech Corp
HKEX:1548
Accrued Liabilities
$165.9m
CAGR 3-Years
7%
CAGR 5-Years
18%
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Accrued Liabilities
ÂĄ106.7m
CAGR 3-Years
83%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hangzhou Tigermed Consulting Co Ltd
Glance View

Founded in 2004, Hangzhou Tigermed Consulting Co., Ltd. emerged as a pivotal player in the flourishing landscape of clinical research services within the pharmaceutical and biotechnology sectors. As a leading contract research organization (CRO), Tigermed has meticulously woven a fabric of comprehensive solutions that span from drug development to clinical trial management. Their expertise extends across various therapeutic areas, underpinning a business model that thrives on facilitating the intricate process through which innovative drugs make their way from concept to market. The company’s robust portfolio of services encompasses clinical operations, regulatory submissions, data management, and biostatistics, effectively addressing the myriad needs of drug development companies looking to streamline operations and accelerate time-to-market. Tigermed’s revenue model primarily revolves around contracts and partnerships with pharmaceutical and biotech companies seeking external expertise in clinical trials. The company's proficiency in managing multinational projects, especially within China and the broader Asia-Pacific region, provides an edge in a competitive global market that increasingly values speed and localized knowledge. Rather than merely providing traditional consulting services, Tigermed capitalizes on cutting-edge technology and a deep understanding of regional regulatory frameworks to offer a seamless and efficient trial process. In doing so, it captures the growing demand for outsourcing drug development work, ensuring steady revenue streams while solidifying its status as a vital partner in the relentless pursuit of medical innovation.

Intrinsic Value
53.36 CNY
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Hangzhou Tigermed Consulting Co Ltd's Accrued Liabilities?
Accrued Liabilities
325.8m CNY

Based on the financial report for Sep 30, 2025, Hangzhou Tigermed Consulting Co Ltd's Accrued Liabilities amounts to 325.8m CNY.

What is Hangzhou Tigermed Consulting Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
35%

Over the last year, the Accrued Liabilities growth was 93%. The average annual Accrued Liabilities growth rates for Hangzhou Tigermed Consulting Co Ltd have been 7% over the past three years , 27% over the past five years , and 35% over the past ten years .

Back to Top